La FDA aprueba la primera pastilla para tratar la enfermedad de Crohn de moderada a grave
VIERNES, 19 de mayo de 2023 (HealthDay News) — Los pacientes con enfermedad de Crohn cuentan ahora con una nueva opción de tratamiento, después de que la Administración de Alimentos y Medicamentos (FDA) de EE. UU. aprobara una pastilla llamada Rinvoq…
Learn MoreWegovy Shows Weight-Loss Effectiveness in Real-World Study
MONDAY, May 22, 2023 (HealthDay News) — It’s a social media darling and one of the hottest prescription medications on the U.S. market. But does Wegovy really help patients lose weight?Yes, a new study suggests.Investigators analyzed data on more tha…
Learn MoreFDA Approves First Pill to Treat Moderate-to-Severe Crohn Disease
FRIDAY, May 19, 2023 (HealthDay News) — Patients with Crohn disease have a new treatment option, following U.S. Food and Drug Administration approval of Rinvoq (upadacitinib).Rinvoq is meant to treat adults with moderately to severely active Crohn di…
Learn MoreAllopurinol May Cut Risk for Neurodegenerative Diseases
FRIDAY, May 19, 2023 (HealthDay News) — Xanthine dehydrogenase/oxidase blockers may reduce the risk for neurodegenerative diseases, according to a study published online May 17 in PLOS ONE.Yizhe Song, from the Washington University School of Medicine…
Learn MoreSex Differences Seen in Cognitive Impairment for Tardive Dyskinesia in Schizophrenia
FRIDAY, May 19, 2023 (HealthDay News) — For schizophrenia patients with tardive dyskinesia (TD), there may be sex differences in cognitive impairment, with a protective effect suggested by female gender, according to a study published in the May issu…
Learn MoreFDA Approves First Pill to Treat Moderate-to-Severe Crohn’s Disease
FRIDAY, May 19, 2023 (HealthDay News) — Patients with Crohn’s disease have a new treatment option, following U.S. Food and Drug Administration approval of a pill called Rinvoq (upadacitinib).Rinvoq is meant to treat adults with moderately to severely…
Learn MoreOne in Five Seniors Report Cost-Related Medication Nonadherence
THURSDAY, May 18, 2023 (HealthDay News) — About one in five older adults reported cost-related medication nonadherence in 2022, according to a study published online May 18 in JAMA Network Open.Stacie B. Dusetzina, Ph.D., from the Vanderbilt Universi…
Learn MoreUn balón gástrico tragable ayuda a las personas a perder peso
MIÉRCOLES, 17 de mayo de 2023 (HealthDay News) — Combinar un balón gástrico tragable con un medicamento para perder peso podría ser una forma de perder un peso corporal significativo, sugiere un estudio reciente. En unos ocho meses de tratamiento com…
Learn MoreBrepocitinib Beneficial for Moderate-to-Severe Psoriatic Arthritis
THURSDAY, May 18, 2023 (HealthDay News) — For patients with moderately to severely active psoriatic arthritis, the tyrosine kinase 2/Janus kinase 1 inhibitor brepocitinib is effective for reducing symptoms, according to a study published online May 1…
Learn MorePeresolimab Found to Be Efficacious for Rheumatoid Arthritis
THURSDAY, May 18, 2023 (HealthDay News) — Peresolimab, a humanized immunoglobulin G1 monoclonal antibody designed to stimulate the endogenous programmed cell death protein 1 (PD-1) inhibitory pathway, is efficacious for patients with rheumatoid arthr…
Learn More